Table 1.
Select characteristics of AIDS-NHL cases and HIV-infected controls from the Women’s Interagency HIV Study
| AIDS-NHL cases (n=22)
|
HIV-infected controls (n=78)
|
p-value | |||
|---|---|---|---|---|---|
| N | (%) | N | (%) | ||
| Baseline characteristics | |||||
| WIHS site | |||||
| New York | 9 | (40) | 24 | (31) | |
| DC | 1 | (5) | 9 | (12) | |
| California | 11 | (50) | 28 | (35) | |
| Chicago | 1 | (5) | 17 | (22) | 0.16 |
| Race/ethnicity | |||||
| African-American, non-Hispanic | 11 | (50) | 47 | (60) | |
| White, non-Hispanic | 8 | (36) | 20 | (26) | |
| Latina/Hispanic | 2 | (9) | 11 | (14) | |
| Other | 1 | (5) | 0 | (0) | 0.18 |
| Education | |||||
| Less than high school | 7 | (32) | 28 | (36) | |
| High school graduate | 6 | (27) | 23 | (30) | |
| More than high school | 9 | (41) | 26 | (34) | 0.82 |
| HCV positivea | |||||
| No | 18 | (82) | 58 | (75) | |
| Yes | 4 | (18) | 19 | (25) | 0.53 |
| Characteristics at AIDS-NHL diagnosis or reference date | |||||
| Reference year | |||||
| 1995–2001 | 16 | (73) | 53 | (68) | |
| 2002–2008 | 6 | (27) | 25 | (32) | 0.67 |
| Age (years) | |||||
| <30 | 4 | (18) | 8 | (10) | |
| 30–39 | 10 | (45) | 41 | (53) | |
| 40–49 | 7 | (32) | 24 | (31) | |
| ≥50 | 1 | (5) | 5 | (6) | 0.76 |
| Cigarette smokingb | |||||
| Never | 5 | (24) | 26 | (34) | |
| Current | 8 | (38) | 38 | (50) | |
| Former | 8 | (38 | 12 | (16 | 0.08 |
| CD4+ T cells/mm3 c | |||||
| <200 | 13 | (72) | 28 | (41) | |
| 200–400 | 3 | (17) | 12 | (18) | |
| >400 | 2 | (11) | 28 | (41) | 0.04 |
| HIV RNA copiesd | |||||
| <4000 | 2 | (11) | 25 | (36) | |
| 4000–20,000 | 4 | (21) | 15 | (22) | |
| >20000 | 13 | (68) | 29 | (42) | 0.07 |
| Prior AIDS diagnosis | |||||
| No | 9 | (41) | 34 | (44) | |
| Yes | 13 | (59) | 44 | (56) | 0.82 |
| Prior HAART exposuree | |||||
| No | 13 | (59) | 41 | (53) | |
| Yes | 9 | (41) | 37 | (47) | 0.66 |
| Tumor subtypef | |||||
| Systemic | 17 | (77) | |||
| Diffuse large B cell lymphoma | 11 | ||||
| Precursor lymphoblastic leukemia/lymphoma, B cell | 2 | ||||
| Burkitt lymphoma | 1 | ||||
| B cell lymphoid neoplasm, NOS | 3 | ||||
| Central Nervous System | 5 | (23) | |||
a
RNA positive or antibody positive at baseline study visit
b
Missing values for three participants
c
Missing values for 14 participants
d
Missing values for 12 participants
e
“No” indicates unexposed at all three serum sampling time points “Yes” indicates exposed at least one time point
f
Classified according to the InterLymph recommendation for epidemiologic research (17).